116 related articles for article (PubMed ID: 23754532)
1. Prediagnostic circulating markers of inflammation and risk of prostate cancer.
Toriola AT; Laukkanen JA; Kurl S; Nyyssönen K; Ronkainen K; Kauhanen J
Int J Cancer; 2013 Dec; 133(12):2961-7. PubMed ID: 23754532
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory biomarker score and cancer: A population-based prospective cohort study.
Morrison L; Laukkanen JA; Ronkainen K; Kurl S; Kauhanen J; Toriola AT
BMC Cancer; 2016 Feb; 16():80. PubMed ID: 26860264
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study.
Stikbakke E; Richardsen E; Knutsen T; Wilsgaard T; Giovannucci EL; McTiernan A; Eggen AE; Haugnes HS; Thune I
Int J Cancer; 2020 Jul; 147(1):84-92. PubMed ID: 31583707
[TBL] [Abstract][Full Text] [Related]
4. The joint impact of prediagnostic inflammatory markers and cardiorespiratory fitness on the risk of cancer mortality.
Pletnikoff PP; Laukkanen JA; Tuomainen TP; Kurl S
Scand J Med Sci Sports; 2018 Feb; 28(2):613-620. PubMed ID: 28759130
[TBL] [Abstract][Full Text] [Related]
5. Obesity, adipokines, and prostate cancer in a prospective population-based study.
Baillargeon J; Platz EA; Rose DP; Pollock BH; Ankerst DP; Haffner S; Higgins B; Lokshin A; Troyer D; Hernandez J; Lynch S; Leach RJ; Thompson IM
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1331-5. PubMed ID: 16835332
[TBL] [Abstract][Full Text] [Related]
6. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.
Stark JR; Li H; Kraft P; Kurth T; Giovannucci EL; Stampfer MJ; Ma J; Mucci LA
Int J Cancer; 2009 Jun; 124(11):2683-9. PubMed ID: 19189403
[TBL] [Abstract][Full Text] [Related]
7. Chronic inflammation and risk of colorectal and other obesity-related cancers: The health, aging and body composition study.
Izano M; Wei EK; Tai C; Swede H; Gregorich S; Harris TB; Klepin H; Satterfield S; Murphy R; Newman AB; Rubin SM; Braithwaite D;
Int J Cancer; 2016 Mar; 138(5):1118-28. PubMed ID: 26413860
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population.
Allin KH; Bojesen SE; Nordestgaard BG
Int J Cancer; 2016 Oct; 139(7):1493-500. PubMed ID: 27194008
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
10. Relation of C-reactive protein, fibrinogen, and cardiorespiratory fitness to risk of systemic hypertension in men.
Jae SY; Kurl S; Laukkanen JA; Lee CD; Choi YH; Fernhall B; Franklin BA
Am J Cardiol; 2015 Jun; 115(12):1714-9. PubMed ID: 25888302
[TBL] [Abstract][Full Text] [Related]
11. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
[TBL] [Abstract][Full Text] [Related]
12. Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry.
Tulloch-Reid MK; McFarlane-Anderson N; Bennett FI; Aiken WD; Jackson MD
Cancer Causes Control; 2017 Nov; 28(11):1313-1321. PubMed ID: 28864928
[TBL] [Abstract][Full Text] [Related]
13. Serum β-carotene in relation to risk of prostate cancer: the Kuopio Ischaemic Heart Disease Risk Factor study.
Karppi J; Kurl S; Laukkanen JA; Kauhanen J
Nutr Cancer; 2012 Apr; 64(3):361-7. PubMed ID: 22420939
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein concentrations and subsequent ovarian cancer risk.
McSorley MA; Alberg AJ; Allen DS; Allen NE; Brinton LA; Dorgan JF; Pollak M; Tao Y; Helzlsouer KJ
Obstet Gynecol; 2007 Apr; 109(4):933-41. PubMed ID: 17400857
[TBL] [Abstract][Full Text] [Related]
15. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers.
Seddon JM; George S; Rosner B; Rifai N
Arch Ophthalmol; 2005 Jun; 123(6):774-82. PubMed ID: 15955978
[TBL] [Abstract][Full Text] [Related]
16. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation.
Van Hemelrijck M; Jungner I; Walldius G; Garmo H; Binda E; Hayday A; Lambe M; Holmberg L; Hammar N
Int J Cancer; 2011 Sep; 129(6):1485-92. PubMed ID: 21792885
[TBL] [Abstract][Full Text] [Related]
17. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
Arthur R; Williams R; Garmo H; Holmberg L; Stattin P; Malmström H; Lambe M; Hammar N; Walldius G; Robinsson D; Jungner I; Van Hemelrijck M
Int J Cancer; 2018 Jun; 142(11):2254-2262. PubMed ID: 29322512
[TBL] [Abstract][Full Text] [Related]
18. Markers of inflammation and weight change in middle-aged adults: results from the prospective MONICA/KORA S3/F3 study.
Holz T; Thorand B; Döring A; Schneider A; Meisinger C; Koenig W
Obesity (Silver Spring); 2010 Dec; 18(12):2347-53. PubMed ID: 20360759
[TBL] [Abstract][Full Text] [Related]
19. Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer.
Berndt SI; Carter HB; Landis PK; Hallfrisch J; Rohrmann S; Metter EJ; Platz EA
Nutrition; 2005 Jun; 21(6):686-90. PubMed ID: 15925292
[TBL] [Abstract][Full Text] [Related]
20. High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: The Tromsø Study.
Dahl K; Ahmed LA; Joakimsen RM; Jørgensen L; Eggen AE; Eriksen EF; Bjørnerem Å
Bone; 2015 Mar; 72():65-70. PubMed ID: 25460573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
